Early successes by partner company, Cancer CRC

Wednesday 29 July, 2009

The Cancer Council Victoria partner company, the Cancer Cooperative Research Centre Pty Ltd (CTx), set up only two years ago, has recorded significant progress in its quest to discover new, effective small molecule cancer drugs from Australian research.

Partners in CTx include The Cancer Council Victoria, St Vincent's Institute, The Walter and Eliza Hall Institute of Medical Research, CSIRO Molecular Health Technologies, Monash University's Institute of Pharmaceutical Sciences, Peter MacCallum Cancer Centre, Griffith University, Bionomics Ltd and Cancer Research Technology Ltd (UK).

CTx works with cancer researchers to discover and develop their promising cancer targets into pre-clinical small molecule drug candidates.

Recent progress:

  • In May, Australian Biotech company Cytopia Limited (ASX:CYT) announced significant progress by CTx towards identification of a preclinical drug candidate based on intellectual property (IP) licensed from Cytopia to CTx. The promising pre-clinical candidate is an inhibitor of the enzyme Focal Adhesion Kinase (FAK), thought to play an important role in growth, invasion, and spread of solid tumours. (From an ASX announcement). Full story: https://www.cancercrc.com/getdoc.php?doc=147394acdf42ff21
  • In mid-June, Novation Pharmaceuticals Inc, Vancouver, Canada and Cancer Therapeutics CRC Pty Ltd Melbourne, Australia, (CTx) announced a joint collaboration to identify potent small-molecule compounds for two very important but highly intractable oncology targets, c-myc and hSSB1. Full story:
    https://www.cancercrc.com/getdoc.php?doc=a13aa37249e7657e